204 The pegbelfermin group showed reductions in LFF and some improvements in inflammation, but the effects on fibrosis regression and MASH resolution did not reach statistical significance. 204 Notably, a parallel trial tested efruxifermin in patients whose liver conditions were similar to those in FALCON2 (F4 fibrosis and compensated cirrhosis).
← all excerpts
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.
1
—
—